NCT00492089 · FLOW

Participant flow

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer · Source last updated 2014-05-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

description
Bevacizumab 7.5 mg/m\^2 intravenous (IV) every 3 weeks.
id
FG000
title
Arm A: Bevacizumab
description
Placebo IV every 3 weeks for two courses, crossover at 6 weeks to receive Bevacizumab 7.5 mg/m\^2 IV as in Arm A.
id
FG001
title
Crossover Arm B: Placebo First, Then Bevacizumab

periods

milestones
achievements
group Id
FG000
num Subjects
5
group Id
FG001
num Subjects
6
type
STARTED
achievements
group Id
FG000
num Subjects
5
group Id
FG001
num Subjects
6
type
COMPLETED
achievements
group Id
FG000
num Subjects
0
group Id
FG001
num Subjects
0
type
NOT COMPLETED
title
First Intervention (6 Weeks)
milestones
achievements
group Id
FG000
num Subjects
5
group Id
FG001
num Subjects
6
type
STARTED
achievements
group Id
FG000
num Subjects
5
group Id
FG001
num Subjects
6
type
COMPLETED
achievements
group Id
FG000
num Subjects
0
group Id
FG001
num Subjects
0
type
NOT COMPLETED
title
Second Intervention (6 Weeks)

pre Assignment Details

Of the 15 patients enrolled, four participants were excluded from the study.

recruitment Details

Recruitment Period: June 20, 2007 to December 07, 2009. All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.

Complete source fields